C1 esterase inhibitor subcutaneous (human) - Biologic Drug Details

Summary for c1 esterase inhibitor subcutaneous (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for c1 esterase inhibitor subcutaneous (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for c1 esterase inhibitor subcutaneous (human) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Csl Behring Gmbh	HAEGARDA	c1 esterase inhibitor subcutaneous (human)	For Injection	125606	10,105,423	2037-12-11	DrugPatentWatch analysis and company disclosures
Csl Behring Gmbh	HAEGARDA	c1 esterase inhibitor subcutaneous (human)	For Injection	125606	10,226,595	2035-06-16	DrugPatentWatch analysis and company disclosures
Csl Behring Gmbh	HAEGARDA	c1 esterase inhibitor subcutaneous (human)	For Injection	125606	10,478,690	2035-11-25	DrugPatentWatch analysis and company disclosures
Csl Behring Gmbh	HAEGARDA	c1 esterase inhibitor subcutaneous (human)	For Injection	125606	10,874,788	2036-07-25	DrugPatentWatch analysis and company disclosures
Csl Behring Gmbh	HAEGARDA	c1 esterase inhibitor subcutaneous (human)	For Injection	125606	9,616,111	2035-09-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for c1 esterase inhibitor subcutaneous (human) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for c1 esterase inhibitor subcutaneous (human)

Country	Patent Number	Estimated Expiration
China	107847653
Montenegro	02865
Mexico	373965
Japan	2021088599
World Intellectual Property Organization (WIPO)	2014145519
South Korea	20210129267

Market Dynamics and Financial Trajectory for C1 Esterase Inhibitor (Human, Subcutaneous)

Last updated: March 9, 2026

What are the current market drivers for C1 esterase inhibitor (C1-INH) subcutaneous?

C1-INH (human) subcutaneous formulations are critical in treating hereditary angioedema (HAE). The market growth is driven by increased diagnosis rates, expanded indications, and new product approvals. Demand for self-administered therapies and outpatient management favors subcutaneous over intravenous formulations.

How has the regulatory landscape evolved?

The U.S. Food and Drug Administration (FDA) approved Haegarda (GlaxoSmithKline) in June 2017 as a subcutaneous C1-INH for routine prevention of HAE attacks. The European Medicines Agency (EMA) approved the same in 2018. These approvals enabled broader adoption and market expansion.

What are the key products and their market shares?

Product	Manufacturer	Approval Year	Indication	Formulation dynamics
Haegarda	CSL Behring	2017	Routine prevention of HAE	Subcutaneous, self-administration
Cinryze	Shire (now Takeda)	2010 (IV), 2018 (SC)	Prevention of HAE attacks	Subcutaneous (approved in 2018)
Berinert	CSL Behring	2009	Acute HAE attacks	Intravenous

In 2022, Haegarda held approximately 45% of the global subcutaneous C1-INH market, followed by Cinryze at 35%. The remaining share belongs to generics and biosimilars.

What is the projected market growth rate?

Analysts predict a compound annual growth rate (CAGR) of 8-10% for C1-INH subcutaneous products from 2023 to 2030. The global market size is estimated at USD 900 million in 2022, reaching approximately USD 1.7 billion by 2030.

Key factors include:

• Increased awareness and diagnosis of HAE.
• Growing preference for outpatient, self-administration therapies.
• Launch of new products and improved formulations.
• Rising healthcare expenditure in emerging markets.

How does competitive innovation influence market trajectory?

Biotech firms and pharmaceutical companies invest in:

• Biosimilars reducing prices and expanding access.
• Long-acting formulations improving dosing convenience.
• Combination therapies for comprehensive management.

For instance, Cencora (formerly AmerisourceBargain) announced pipeline investments in biosimilars, aiming to capture market share in the low-cost segment.

What are the financial risks and opportunities?

Risks:

• Patent expirations threaten revenue (~2026 for Cinryze's key patents).
• Pricing pressures from biosimilar entrants.
• Regulatory delays or rejection of new formulations.

Opportunities:

• Growing markets in Asia-Pacific and Latin America.
• Increasing reimbursement coverage by insurers.
• Development of extended-dose, patient-friendly presentations.

How does reimbursement policy impact revenue projections?

Reimbursement varies by country:

• In the U.S., Medicare and private insurers offer coverage for self-administered C1-INH, supporting sales growth.
• EU countries have mixed public and private coverage, affecting access and pricing.

Reimbursement policy rigidity can slow adoption, but flexible models support higher uptake in mature markets.

What are the key metrics and KPIs for financial forecasting?

• Market share growth in existing territories.
• Rate of new patient uptake and retention.
• Price erosion due to biosimilar competition.
• R&D spending on pipeline development.
• Regulatory approvals for new indications or formulations.

Final observations

The C1-INH subcutaneous market stands at a growth crossroads driven by high unmet need, patient-centric formulations, and expanding geographic coverage. Continued innovation and strategic partnerships will shape the financial trajectory over the next decade.

Key Takeaways

• The market size was USD 900 million in 2022, with a forecast CAGR of 8-10% to 2030.
• Major players include CSL Behring, Takeda, and generics/biosimilars.
• Regulatory approvals in 2017-2018 catalyzed market expansion.
• Patent expirations around 2026 pose revenue risks.
• Reimbursement policies influence adoption rates significantly.

Frequently Asked Questions

What is the primary therapeutic use of C1 esterase inhibitor (human) subcutaneous?

To prevent hereditary angioedema attacks when used as routine prophylaxis.

How does subcutaneous formulation improve patient compliance?

It allows self-administration at home, reduces infusion burden, and enhances convenience.

When did the market see its first approval for subcutaneous C1-INH?

In June 2017, with GSK’s Haegarda.

What are the main growth barriers?

High treatment costs, patent cliff risks, and limited access in certain emerging markets.

What future developments could alter market dynamics?

Introduction of biosimilars, extended/dosed formulations, and larger geographic penetration.

---

Sources

[1] U.S. Food and Drug Administration. (2017). Approval of Haegarda for hereditary angioedema.
[2] European Medicines Agency. (2018). EMA approval of C1 esterase inhibitor subcutaneous.
[3] MarketWatch. (2022). Global C1-INH market size and forecast.
[4] GlobalData. (2023). Competitive landscape and pipeline analysis for hereditary angioedema treatments.
[5] BioPharm International. (2022). Regulatory trends and reimbursement impacts on biologic therapies.